Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Zink

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Journal of Clinical Psychopharmacology|November 3, 2016
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Pharmacopsychiatry|May 8, 2018
Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Journal of Clinical Psychopharmacology|June 19, 2018
Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Sarah Eisenacher, et al.
Postgraduate Medicine|February 5, 2011
Switching among antipsychotics in everyday clinical practice: focus on ziprasidoneAlessandro Rossi, Fernando Cañas, Andrea Fagiolini, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 20, 2012
Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatmentMartina Von Wilmsdorff, Carolin Blaich, Mathias Zink, et al.
European Archives of Psychiatry and Clinical Neuroscience|December 13, 2018
Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapineDaniela Mier, Frederike Schirmbeck, Gabriela Stoessel, et al.
Psychiatry Research|April 18, 2016
Bias against disconfirmatory evidence in the 'at-risk mental state' and during psychosisSarah Eisenacher, Franziska Rausch, Daniela Mier, et al.
Schizophrenia Research|October 4, 2015
Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern studyJosep Maria Haro, Carlo Altamura, Ricardo Corral, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 1, 2005
Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactionsStephanie Ridder, Sabine Chourbaji, Rainer Hellweg, et al.
Social Psychiatry and Psychiatric Epidemiology|January 18, 2018
Health-related quality of life in outpatients with schizophrenia: factors that determine changes over timeCristina Domenech, Carlo Altamura, Corrado Bernasconi, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Journal of Clinical Psychopharmacology|November 3, 2016
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Pharmacopsychiatry|May 8, 2018
Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Antje Lewien, et al.
Journal of Clinical Psychopharmacology|June 19, 2018
Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH StudySusanne Englisch, Hanna Sophie Jung, Sarah Eisenacher, et al.
Postgraduate Medicine|February 5, 2011
Switching among antipsychotics in everyday clinical practice: focus on ziprasidoneAlessandro Rossi, Fernando Cañas, Andrea Fagiolini, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 20, 2012
Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatmentMartina Von Wilmsdorff, Carolin Blaich, Mathias Zink, et al.
European Archives of Psychiatry and Clinical Neuroscience|December 13, 2018
Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapineDaniela Mier, Frederike Schirmbeck, Gabriela Stoessel, et al.
Psychiatry Research|April 18, 2016
Bias against disconfirmatory evidence in the 'at-risk mental state' and during psychosisSarah Eisenacher, Franziska Rausch, Daniela Mier, et al.
Schizophrenia Research|October 4, 2015
Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern studyJosep Maria Haro, Carlo Altamura, Ricardo Corral, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 1, 2005
Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactionsStephanie Ridder, Sabine Chourbaji, Rainer Hellweg, et al.
Social Psychiatry and Psychiatric Epidemiology|January 18, 2018
Health-related quality of life in outpatients with schizophrenia: factors that determine changes over timeCristina Domenech, Carlo Altamura, Corrado Bernasconi, et al.
Pageof 12